Mirtazapina Azevedos (Mirtazapine)

Mirtazapine, a NaSSA antidepressant, is used chiefly in the treatment of depressive illnesses. By enhancing noradrenergic and serotonergic neurotransmission, it helps to correct the neurochemical imbalances that underlie depressive symptomatology. Clinicians prescribe it for patients diagnosed with major depressive disorder, where it has demonstrated efficacy in reducing depressive scores and improving functional outcomes.

• Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients.
• Treatment‑resistant depression (adjunct): may be added when response to first‑line antidepressants is inadequate.

• Mirtazapine acts as an antagonist at central α2‑adrenergic receptors, which disinhibits norepinephrine release, and selectively blocks 5‑HT2 and 5‑HT3 serotonin receptors. This combined action increases synaptic concentrations of norepinephrine and serotonin at the 5‑HT1 receptors, enhancing mood‑regulating pathways while reducing side‑effects associated with other serotonergic agents. The drug also exhibits moderate antagonism at histamine H1 receptors, contributing to its sedative properties, and has weak anticholinergic activity.

Mirtazapine may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects

• Sedation or drowsiness: feeling unusually sleepy, especially after the first doses.
• Increased appetite and weight gain: heightened hunger leading to gradual weight increase.
• Dry mouth: reduced salivation causing throat discomfort.
• Constipation: infrequent bowel movements or hard stools.
• Dizziness: sensation of light‑headedness or imbalance.
• Fatigue: persistent lack of energy and motivation.

Serious or Rare Side Effects

• Agranulocytosis or severe neutropenia: dangerously low white‑blood‑cell counts requiring monitoring.
• Hepatic dysfunction or hepatitis: liver enzyme elevations or inflammation.

When prescribing mirtazapine, clinicians should observe several precautionary measures to ensure patient safety.

• Weight monitoring: track body weight regularly due to risk of weight gain.
• Suicidality assessment: evaluate for emerging suicidal thoughts, especially early in treatment.
• Liver function: assess hepatic enzymes before initiation and periodically during therapy.
• CNS depressant use: use caution when combined with alcohol or other sedatives.
• Blood dyscrasias: monitor complete blood count if patient shows signs of infection.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Mirtazapine can interact with several medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome.
• Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): may precipitate serotonin syndrome.
• CNS depressants (e.g., benzodiazepines, opioids): enhanced sedation and respiratory depression.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase mirtazapine plasma concentrations.
• Alcohol: additive central nervous system depression.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs: additive blood‑pressure lowering effect.
• Anticholinergic medications: may exacerbate anticholinergic burden.
• Carbamazepine: may reduce mirtazapine levels, decreasing efficacy.
• Warfarin: potential alteration of INR, requiring monitoring.
• Lithium: possible increase in lithium levels, monitor serum concentration.